Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous adipose-derived mesenchymal stem cells after knee microfracture
ACTRN12614000812695Phase 2Terminated
- Sponsor
- Magellan Stem Cells
- Start
- Sep 2014
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of autologous adipose-derived mesenchymal stromal cells in cartilage defect of knee (2 arms), sponsored by Magellan Stem Cells. Primary endpoints: MRI assessed cartilage volume, MRI assessed cartilage quality and 1 more. Started Sep 2014; status: terminated.
02
Drugs
autologous adipose-derived mesenchymal stromal cells
03
Conditions
cartilage defect of knee
Beyond the preview
Go deeper on ACTRN12614000812695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000812695.